patients

1:39
Uncovering the genomic landscape of prostate cancer
Joaquin Mateo
1:22
Drug shortages around the world: why communication is key
Fatima Cardoso
3:24
Interesting topics presented at ESMO 2017
Fatima Cardoso
0:43
Why should physicians and patients be educated about novel drugs?
Eric Jonasch
0:57
When is the optimal time to use PARP inhibitors in prostate cancer patients?
Joaquin Mateo
1:25
PARP inhibitors: their applications and efficacy against prostate cancer
Joaquin Mateo
0:50
Genomic aberrations in prostate cancer
Joaquin Mateo
4:13
What have we learned from recent clinical trials in early breast cancer treatment?
Elzbieta Senkus-Konefka
1:01
What is the eHealth 2020 action plan?
Terje Peetso
1:21
Side effects of chemotherapy vs. immunotherapy
Andrea B. Apolo
0:49
The advantages of clinical trials
Andrea B. Apolo
2:40
Combining agents to improve response rates in genitourinary cancer
Andrea B. Apolo
4:55
Pertuzumab in HER2+ breast cancer
Gunter von Minckwitz
1:22
The importance of knowing the molecular profile of a patient’s tumor
Howard Burris
0:52
The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers
Howard Burris
1:59
Diversity of cancer patient concerns revealed through Holistic Needs Assessment
Keith Mitchell et al.
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals